DeepMed Research

Zhejiang Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.zchospital.com

Clinical Trials

Ciprofol EC50 for Inducing Loss of Consciousness in Elderly Patients

Phase 4

Recruiting

Conditions: Elderly Patients

Interventions: Drug: Ciprofol dose 0.3mg/Kg
Drug: Ciprofol dose 0.4mg/Kg
Drug: Ciprofol dose 0.2mg/Kg

First Posted Date: 2024-02-12

Last Posted Date: 2024-05-29

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 150

Registration Number: NCT06253078

Locations: 🇨🇳
Jiangling Wang, Hangzhou, Zhejiang, China

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Phase 2

Not yet recruiting

Conditions: Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer
Female Breast Cancer Patients
HRD Positive Advanced Breast Cancer

Interventions: Drug: Adebrelimab plus Fluzoparib

First Posted Date: 2024-02-12

Last Posted Date: 2024-02-12

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT06254066

The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity

Phase 3

Recruiting

Conditions: Cardiotoxicity Induced by Drug Therapy for Breast Cancer

Interventions: Drug: Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)

First Posted Date: 2024-01-19

Last Posted Date: 2024-01-19

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 276

Registration Number: NCT06214195

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Phase 2

Suspended

Conditions: Biliary Tract Carcinoma

Interventions: Drug: SBRT Sequential Surufatinib Combined With Immunotherapy

First Posted Date: 2024-01-10

Last Posted Date: 2024-10-14

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 34

Registration Number: NCT06199882

Locations: 🇨🇳
Liu luying, Hangzhou, Zhejiang, China

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

Phase 2

Active, not recruiting

Conditions: PDL1 Gene Mutation
Non-small Cell Lung Cancer

Interventions: Drug: Serplulimab

First Posted Date: 2024-01-08

Last Posted Date: 2024-01-08

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 23

Registration Number: NCT06195683

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Phase 1

Not yet recruiting

Conditions: CRC
Metastatic Colorectal Adenocarcinoma
Metastatic Colorectal Cancer

Interventions: Drug: Experimental
Drug: Active Comparator

First Posted Date: 2024-01-08

Last Posted Date: 2024-01-08

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 220

Registration Number: NCT06195670

Locations: 🇨🇳
Ji Zhu, Hangzhou, Zhejiang, China

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: sintilimab

First Posted Date: 2024-01-05

Last Posted Date: 2024-01-05

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 31

Registration Number: NCT06190639

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation

Not Applicable

Recruiting

Conditions: Liver Cancer
Ciprofol

Interventions: Drug: Propofol
Drug: Ciprofol

First Posted Date: 2023-12-21

Last Posted Date: 2023-12-21

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 80

Registration Number: NCT06178926

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone

Phase 4

Completed

Conditions: Liver Cancer

Interventions: Drug: Liposomal bupivacaine
Drug: Bupivacaine Hydrochloride combined with dexamethasone

First Posted Date: 2023-12-15

Last Posted Date: 2024-12-04

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 96

Registration Number: NCT06173466

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Phase 1

Not yet recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Sindilimab
Drug: Nab-paclitaxel
Drug: Lenvatinib

First Posted Date: 2023-11-20

Last Posted Date: 2023-11-20

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 58

Registration Number: NCT06140576

Locations: 🇨🇳
ZhejiangCH, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy